NP47827 Multiple Sclerosis Medicines

The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)

Value
£30,403,887
Published
13 Nov 2026
Deadline
Not stated
Procedure
Not stated
Category
33600000 — Pharmaceutical products
Location
UKM
Notice reference
101240-2026

Requirements summary

PSD Scotland, on behalf of NHS Scotland, is planning to establish framework agreements for supply of Multiple Sclerosis medicines, split into three lots: glatiramer acetate, interferon beta-1a and natalizumab; fingolimod, teriflunomide and dimethyl fumarate; and cladribine tablets. The estimated value is GBP 30,403,887 over a maximum 48-month duration, with full goods and volumes to be provided in ITT documents once published.

Key requirements

  • Framework agreement for supply of Multiple Sclerosis medicines to NHS Scotland and Integrated Joint Boards
  • Lot 1: glatiramer acetate, interferon beta-1a and natalizumab, awarded as unranked multi-supplier framework per product line
  • Lot 2: fingolimod, teriflunomide and dimethyl fumarate, awarded as ranked multi-supplier framework per product line
  • Lot 3: cladribine tablets, awarded as ranked multi-supplier framework per product line
  • Estimated value GBP 30,403,887 covering a maximum 48-month duration including extensions
  • Medicine range subject to removal or replacement due to changing litigation landscape; volumes and full goods details to be confirmed in ITT documents
NP47827 Multiple Sclerosis Medicines — The Common Servi… | ProposAI